On Friday, Citi issued a downgrade for Ono Pharmaceutical Co., Ltd (4528:JP) (OTC: OPHLY), shifting the stock's rating from Neutral to Sell and adjusting the price target to JPY1,900 from the previous JPY2,600. The revision reflects Citi's updated earnings forecasts for the pharmaceutical company in light of several factors impacting its financial outlook.
The change in Citi's stance comes as Ono Pharmaceutical faces the upcoming expiration of its Opdivo patent. The company is attempting to mitigate the impact of this "patent cliff" through various strategies, including the acquisition of Deciphera, the global development of Velexbru, and other in-house developments and licensing efforts. Despite these initiatives, Citi anticipates an expansion of losses for Ono Pharmaceutical in the short term.
The acquisition of Deciphera, valued at $2.4 billion, is a significant investment for Ono, which the company aims to make profitable by 2027. However, Citi notes that this acquisition, along with increasing research and development (R&D) and selling, general, and administrative (SG&A) expenses as the company expands globally, are contributing to the downward revision of earnings forecasts.
Citi has incorporated the impact of Deciphera into its earnings projections for Ono Pharmaceutical, leading to the reduced medium-term forecasts. As a result of these adjustments, Citi's analysis suggests an expected total return of approximately -13%, prompting the firm to lower its recommendation to Sell.
InvestingPro Insights
Amid the challenges outlined by Citi's recent downgrade of Ono Pharmaceutical, data and insights from InvestingPro provide a broader perspective on the company's financial health and market position. Notably, Ono Pharmaceutical boasts a strong balance sheet, with more cash than debt, and has maintained dividend payments for 33 consecutive years, demonstrating a commitment to shareholder returns. This is supported by a high shareholder yield and a track record of raising dividends for three consecutive years. Moreover, the company trades at a low P/E ratio of 8.44, suggesting it may be undervalued relative to its near-term earnings growth.
InvestingPro data highlights a robust gross profit margin of 74.71% over the last twelve months as of Q4 2024, indicating efficient cost management and a strong ability to generate income from sales. Additionally, with a revenue growth of 12.41% during the same period, Ono Pharmaceutical shows promising signs of expansion despite the patent expiration concerns. The company's valuation implies a strong free cash flow yield, which could signal an attractive investment opportunity for those looking beyond the immediate challenges.
For investors seeking more in-depth analysis, InvestingPro offers a range of additional tips, including insights into Ono Pharmaceutical's low price volatility, its status as a prominent player in the Pharmaceuticals industry, and its capacity to cover interest payments comfortably. There are 12 more InvestingPro Tips available, providing a comprehensive view of the company's strengths and potential risks. Interested readers can access these valuable insights and take advantage of an exclusive offer using coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.